Evidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart disease risk, treat sleep apnea and address other health issues may help...
Bhanvi Satija And Sriparna Roy - Evidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart disease risk, treat sleep apnea and address other health issues may help convince more men to use them, five doctors who prescribe the medicines regularly told Reuters.
Yet obesity rates remain similar for both men and women at 43% and 42%, respectively, according to U.S. government data. The drugs, from a class of medicines that also treat type 2 diabetes called GLP-1 agonists, are also being considered to cut the risk or progression of kidney disease and for alcohol abuse, among other health issues. Such new uses could shift the gender balance, doctors said.
Other physicians suggested that some men may be more open to weight-loss drugs based on recommendations from women in their lives taking the medicines. Clinical trials that tested Wegovy and Zepbound for weight loss primarily enrolled women. Lilly's sleep apnea trial and Novo's heart disease study both recruited more than 70% male patients, the drugmakers have said.
However, both ACE's Dr. Scott Isaacs and Dr. Pamela Douglas from ACC pointed to a more balanced use between genders when the treatments are prescribed for diabetes, for which they were initially approved.
Obesity Obese Weight Loss Sleep Sleep Apnea Sleep Apnoea Sleep Disturbance Abnormal Sleep Pattern Sleep Disorder Somnipathy Heart Alcoholism Alcohol Dependence Obstructive Sleep Apnea Obstructive Sleep Apnea Syndrome Obstructive Sleep Apnoea Obstructive Sleep Apnoea Syndrome Exercise Physical Activity Addiction Alcohol Abuse Renal Disease Kidney Disease
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Wegovy users keep weight off for 4 years: How Wegovy helps the heartPatients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker’s case to insurers and governments to cover the cost of the effective but expensive drug.
Lire la suite »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Lire la suite »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro.
Lire la suite »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro. The drugmaker said Friday that it was more than doubling its investment in a site near its Indianapolis headquarters.
Lire la suite »
Mounjaro And Zepbound Shortages Targeted With $5.3 Billion Eli Lilly InvestmentI cover breaking news for Forbes. Before Forbes, I worked as a reporter for USA Today in Asheville and Black Mountain, North Carolina. I received my bachelor's degree in journalism from Auburn University and my master's degree in journalism from Northwestern University.
Lire la suite »
Lilly now investing $9B at Lebanon manufacturing site to boost production for Zepbound, MounjaroThe letter claims the city wants to offer Keystone Group 'fair market value' for the roughly 19 remaining acres.
Lire la suite »